Associations of rs3918242 and rs2285053 MMP-9 and MMP-2 polymorphisms with the risk, severity, and short- and long-term complications of degenerative mitral valve diseases: A 4.8-year prospective cohort study

Autor: Calogera Pisano, Alberto Allegra, Carmela Rita Balistreri, Giuseppina Candore, Giovanni Ruvolo, Domenico Lio, Oreste Fabio Triolo, Vincenzo Argano, Floriana Crapanzano
Přispěvatelé: Balistreri, C., Allegra, A., Crapanzano, F., Pisano, C., Triolo, O., Argano, V., Candore, G., Lio, D., Ruvolo, G.
Jazyk: angličtina
Rok vydání: 2016
Předmět:
Male
Pathology
Heart Valve Diseases
Disease
030204 cardiovascular system & hematology
Matrix metalloproteinase
rs3918242
rs243865
rs2285053 MMP-2 and MMP-9 gene SNP

Degenerative forms of mitral valve diseases
Management and outcome
Metalloproteinases
rs3918242
rs243865
rs2285053 MMP-2 and MMP-9 gene SNPs

Aged
Cohort Studies
Female
Genetic Predisposition to Disease
Genotype
Humans
Matrix Metalloproteinase 2
Matrix Metalloproteinase 9
Middle Aged
Mitral Valve
Prospective Studies
Risk Factors
Polymorphism
Single Nucleotide

0403 veterinary science
0302 clinical medicine
rs2285053 MMP-2 and MMP-9 gene SNPs
Natriuretic peptide
Prospective cohort study
MVDS
Metalloproteinase
04 agricultural and veterinary sciences
General Medicine
Single Nucleotide
Pathophysiology
rs3918242
Cardiology and Cardiovascular Medicine
Degenerative forms of mitral valve disease
medicine.medical_specialty
040301 veterinary sciences
medicine.drug_class
Single-nucleotide polymorphism
2734
Pathology and Forensic Medicine
03 medical and health sciences
Internal medicine
medicine
rs243865
Polymorphism
business.industry
Settore MED/23 - Chirurgia Cardiaca
business
Popis: Background Degenerative forms of mitral valve diseases (MVDs) are very complex pathologies. Thus, it is difficult to make generalizations about the disease pathways or genetic risk factors contributing to these diseases. However, a key role of metalloproteinases (MMPs) in their pathophysiology is emerging. Thus, we performed for the first time a perspective study to assess eventual associations of some functional single nucleotide polymorphisms (SNPs) in MMP-2 and MMP-9 genes with the MVD risk, symptom severity, and short- and long-term (4.8 years) complications. Materials and methods For this purpose, 90 patients and two control groups were genotyped for rs3918242, rs243865, and rs2285053 MMP-2 and MMP-9 gene SNPs, and systemic levels of pro-atrial natriuretic peptide (pro-ANP) and two enzymes were quantified and correlated to genotypes of MMP-2 and MMP-9 SNPs studied. In addition, associations between these SNPs and symptom severity and short- and long-term (4.8 years) complications were evaluated. Results Interestingly, rs3918242 MMP-9 and rs2285053 MMP-2 SNPs were significantly represented in cases than two control groups and were associated with a higher MVD risk, as demonstrated using dominant/recessive models. Cases stratified for NYHA symptoms and particularly those NYHA III+IV with rs3918242 CT+TT MMP-9 and rs2285053CT+TT genotypes also showed higher severity related to significant higher systemic levels of MMP enzymes and pro-ANP at enrolment and 4.8 follow-up times. In addition, cases with these genotypes and particularly those NYHA III+IV had a very significant percentage of complications, particularly at the 4.8 follow-up. Surprisingly, 20% of patient controls developed MVD at 4.8-year follow-up and were carriers of these genotypes. Conclusion Thus, the associations observed seem to suggest that the two SNPs might represent useful biomarkers and targets for preventing and monitoring MVDs and developing personalized treatments, consenting a more appropriate management and outcome.
Databáze: OpenAIRE